HC Wainwright Has Optimistic Opinion of TVRD FY2026 Earnings

Tvardi Therapeutics, Inc. (NASDAQ:TVRD – Free Report) – Analysts at HC Wainwright boosted their FY2026 earnings estimates for Tvardi Therapeutics in a report issued on Friday, November 13th. HC Wainwright analyst S. Nik now expects that the company will earn ($2.32) per share for the year, up from their prior forecast of ($2.56). The consensus estimate for Tvardi Therapeutics’ current full-year earnings is ($2.23) per share. HC Wainwright also issued estimates for Tvardi Therapeutics’ Q4 2026 earnings at ($0.50) EPS, FY2027 earnings at ($1.51) EPS and FY2028 earnings at ($1.56) EPS.

Other analysts have also issued research reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, October 2nd. Wall Street Zen downgraded Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, November 1st. BTIG Research dropped their target price on Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Chardan Capital started coverage on Tvardi Therapeutics in a research note on Tuesday, October 20th. They set a “buy” rating for the company. Finally, Lucid Cap Mkts raised shares of Tvardi Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.40.

View Our Latest Stock Analysis on TVRD

Tvardi Therapeutics Price Performance

NASDAQ TVRD opened at $1.10 on Tuesday. Tvardi Therapeutics has a 1-year low of $0.77 and a 1-year high of $5.69. The business’s fifty day moving average price is $1.22 and its 200-day moving average price is $2.58.

Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) last issued its earnings results on Friday, November 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.03.

Hedge Funds Weigh In On Tvardi Therapeutics

A number of institutional investors have recently bought and sold shares of TVRD. Susquehanna International Group LLP bought a new stake in Tvardi Therapeutics during the second quarter valued at about $63,000. BlackRock Inc. bought a new position in shares of Tvardi Therapeutics in the second quarter worth about $181,000. Finally, GSA Capital Partners LLP purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at about $34,000. 44.66% of the stock is owned by institutional investors.

Tvardi Therapeutics Company Profile

(Get Free Report)

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for cancer and fibrotic diseases. The company’s research focuses on STAT3, a protein involved in processes that can contribute to tumor growth and fibrosis. Its lead drug candidate, TTI-101, is an oral small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. Tvardi is also advancing additional drug candidates based on its STAT3 research platform. Headquartered in The Woodlands, Texas, Tvardi is focused on research and clinical development; its investigational candidates are not established commercial products.

Featured Articles

Receive News & Ratings for Tvardi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tvardi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.